Neurotoxin-Induced Rodent Models of Parkinson's Disease: Benefits and Drawbacks
Overview
Authors
Affiliations
Parkinson's disease (PD), the second most common neurodegenerative disorder, is characterized by cardinal motor impairments, including akinesia and tremor, as well as by a host of non-motor symptoms, including both autonomic and cognitive dysfunction. PD is associated with a death of nigral dopaminergic neurons, as well as the pathological spread of Lewy bodies, consisting predominantly of the misfolded protein alpha-synuclein. To date, only symptomatic treatments, such as levodopa, are available, and trials aiming to cure the disease, or at least halt its progression, have not been successful. Wong et al. (2019) suggested that the lack of effective therapy against neurodegeneration in PD might be attributed to the fact that the molecular mechanisms standing behind the dopaminergic neuronal vulnerability are still a major scientific challenge. Understanding these molecular mechanisms is critical for developing effective therapy. Thirty-five years ago, Calne and William Langston (1983) raised the question of whether biological or environmental factors precipitate the development of PD. In spite of great advances in technology and medicine, this question still lacks a clear answer. Only 5-15% of PD cases are attributed to a genetic mutation, with the majority of cases classified as idiopathic, which could be linked to exposure to environmental contaminants. Rodent models play a crucial role in understanding the risk factors and pathogenesis of PD. Additionally, well-validated rodent models are critical for driving the preclinical development of clinically translatable treatment options. In this review, we discuss the mechanisms, similarities and differences, as well as advantages and limitations of different neurotoxin-induced rat models of PD. In the second part of this review, we will discuss the potential future of neurotoxin-induced models of PD. Finally, we will briefly demonstrate the crucial role of gene-environment interactions in PD and discuss fusion or dual PD models. We argue that these models have the potential to significantly further our understanding of PD.
Monoamine Oxidase Inhibitors in Toxic Models of Parkinsonism.
Buneeva O, Medvedev A Int J Mol Sci. 2025; 26(3).
PMID: 39941014 PMC: 11818313. DOI: 10.3390/ijms26031248.
Flavonoids as Potential Therapeutics Against Neurodegenerative Disorders: Unlocking the Prospects.
Faysal M, Dehbia Z, Zehravi M, Sweilam S, Akiful Haque M, Kumar K Neurochem Res. 2024; 49(8):1926-1944.
PMID: 38822985 DOI: 10.1007/s11064-024-04177-x.
Experimental Models to Study Immune Dysfunction in the Pathogenesis of Parkinson's Disease.
Saponjic J, Mejias R, Nikolovski N, Dragic M, Canak A, Papoutsopoulou S Int J Mol Sci. 2024; 25(8).
PMID: 38673915 PMC: 11050170. DOI: 10.3390/ijms25084330.
Emerging Role of Environmental Epitranscriptomics and RNA Modifications in Parkinson's Disease.
Gionco J, Bernstein A J Parkinsons Dis. 2024; 14(4):643-656.
PMID: 38578904 PMC: 11191529. DOI: 10.3233/JPD-230457.
Evaluating Motor Dysfunction and Oxidative Stress Induced by Trichloroethylene in Wistar Rats.
Srivastava R, Chauhan K, Sharma R Methods Mol Biol. 2024; 2761:499-510.
PMID: 38427258 DOI: 10.1007/978-1-0716-3662-6_34.